ES2742898T3 - Composiciones de protrombina humana y factor X activado para mejorar la hemostasia en el tratamiento de trastornos hemorrágicos - Google Patents
Composiciones de protrombina humana y factor X activado para mejorar la hemostasia en el tratamiento de trastornos hemorrágicos Download PDFInfo
- Publication number
- ES2742898T3 ES2742898T3 ES15712018T ES15712018T ES2742898T3 ES 2742898 T3 ES2742898 T3 ES 2742898T3 ES 15712018 T ES15712018 T ES 15712018T ES 15712018 T ES15712018 T ES 15712018T ES 2742898 T3 ES2742898 T3 ES 2742898T3
- Authority
- ES
- Spain
- Prior art keywords
- fii
- fxa
- approximately
- composition
- hemophilia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 208000031169 hemorrhagic disease Diseases 0.000 title claims abstract description 43
- 108010074860 Factor Xa Proteins 0.000 title claims abstract description 9
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 title claims description 6
- 229940039715 human prothrombin Drugs 0.000 title claims description 6
- 230000023597 hemostasis Effects 0.000 title description 5
- 108010094028 Prothrombin Proteins 0.000 claims abstract description 10
- 102100027378 Prothrombin Human genes 0.000 claims abstract description 10
- 229940039716 prothrombin Drugs 0.000 claims abstract description 10
- 208000032843 Hemorrhage Diseases 0.000 claims description 33
- 239000003112 inhibitor Substances 0.000 claims description 30
- 208000009292 Hemophilia A Diseases 0.000 claims description 23
- 208000009429 hemophilia B Diseases 0.000 claims description 17
- 230000007812 deficiency Effects 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000031220 Hemophilia Diseases 0.000 claims description 11
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 10
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 10
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 9
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 7
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 7
- 102100036537 von Willebrand factor Human genes 0.000 claims description 7
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 6
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 6
- 229960001134 von willebrand factor Drugs 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000033316 Acquired hemophilia A Diseases 0.000 claims description 3
- 208000002004 Afibrinogenemia Diseases 0.000 claims description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 3
- 206010053567 Coagulopathies Diseases 0.000 claims description 3
- 208000033131 Congenital factor II deficiency Diseases 0.000 claims description 3
- 206010016076 Factor II deficiency Diseases 0.000 claims description 3
- 208000007646 Hypoprothrombinemias Diseases 0.000 claims description 3
- 208000015294 blood coagulation disease Diseases 0.000 claims description 3
- 201000007182 congenital afibrinogenemia Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 201000007183 prothrombin deficiency Diseases 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000008366 buffered solution Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 44
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 34
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 34
- 108010054218 Factor VIII Proteins 0.000 description 29
- 102000001690 Factor VIII Human genes 0.000 description 29
- 229960000301 factor viii Drugs 0.000 description 29
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- 108090000190 Thrombin Proteins 0.000 description 20
- 229960004072 thrombin Drugs 0.000 description 20
- 208000034158 bleeding Diseases 0.000 description 19
- 230000000740 bleeding effect Effects 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 208000007536 Thrombosis Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000003114 blood coagulation factor Substances 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 9
- 238000005345 coagulation Methods 0.000 description 9
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 8
- 206010016077 Factor IX deficiency Diseases 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 108010000499 Thromboplastin Proteins 0.000 description 6
- 102000002262 Thromboplastin Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002947 procoagulating effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000009256 replacement therapy Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000005376 factor X deficiency Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 201000007371 Factor XIII Deficiency Diseases 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000007386 factor VII deficiency Diseases 0.000 description 3
- 201000007219 factor XI deficiency Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000032182 acquired hemophilia B Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000007382 factor V deficiency Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 101100008047 Caenorhabditis elegans cut-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
- 208000026552 Severe hemophilia A Diseases 0.000 description 1
- 108010059382 Zea mays trypsin inhibitor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 108010013773 recombinant FVIIa Proteins 0.000 description 1
- 229940068953 recombinant fviia Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012032 thrombin generation assay Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953496P | 2014-03-14 | 2014-03-14 | |
| PCT/US2015/020361 WO2015138847A1 (en) | 2014-03-14 | 2015-03-13 | Compositions of human prothrombin and activated factor x for improving hemostasis in the treatment of bleeding disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2742898T3 true ES2742898T3 (es) | 2020-02-17 |
Family
ID=52727470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15712018T Active ES2742898T3 (es) | 2014-03-14 | 2015-03-13 | Composiciones de protrombina humana y factor X activado para mejorar la hemostasia en el tratamiento de trastornos hemorrágicos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150258182A1 (enExample) |
| EP (1) | EP3116534B1 (enExample) |
| JP (1) | JP6535036B2 (enExample) |
| CN (1) | CN106413744B (enExample) |
| AU (1) | AU2015229222C1 (enExample) |
| ES (1) | ES2742898T3 (enExample) |
| NZ (1) | NZ724105A (enExample) |
| TW (1) | TWI653047B (enExample) |
| WO (1) | WO2015138847A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI653047B (zh) | 2014-03-14 | 2019-03-11 | 百特製藥公司 | 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物 |
| AU2018217375B2 (en) * | 2017-02-09 | 2024-04-18 | Csl Behring Gmbh | A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings |
| EP3590528A1 (en) | 2018-07-06 | 2020-01-08 | Octapharma AG | Fx activation process and its use in the preparation of a fxa composition |
| AU2022426762A1 (en) | 2021-12-30 | 2024-07-04 | Baxter Healthcare Sa | Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287180A (en) | 1980-01-28 | 1981-09-01 | Baxter Travenol Laboratories, Inc. | Method for treating blood clotting factor inhibitors |
| DK0796623T3 (da) * | 1996-03-20 | 2005-08-01 | Baxter Ag | Farmaceutisk præparat til behandling af blodkoagulationslidelser |
| US9956272B2 (en) | 2007-05-30 | 2018-05-01 | Bio Products Laboratory Limited | Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same |
| US20130029030A1 (en) * | 2010-03-15 | 2013-01-31 | Kristian Larsen | Method for promotion of hemostasis and/or wound healing |
| TWI653047B (zh) | 2014-03-14 | 2019-03-11 | 百特製藥公司 | 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物 |
-
2015
- 2015-03-12 TW TW104107965A patent/TWI653047B/zh active
- 2015-03-13 JP JP2016575629A patent/JP6535036B2/ja active Active
- 2015-03-13 CN CN201580022141.6A patent/CN106413744B/zh active Active
- 2015-03-13 ES ES15712018T patent/ES2742898T3/es active Active
- 2015-03-13 US US14/658,006 patent/US20150258182A1/en not_active Abandoned
- 2015-03-13 AU AU2015229222A patent/AU2015229222C1/en active Active
- 2015-03-13 EP EP15712018.9A patent/EP3116534B1/en not_active Revoked
- 2015-03-13 WO PCT/US2015/020361 patent/WO2015138847A1/en not_active Ceased
- 2015-03-13 NZ NZ724105A patent/NZ724105A/en unknown
-
2018
- 2018-12-21 US US16/231,195 patent/US11160850B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI653047B (zh) | 2019-03-11 |
| AU2015229222B2 (en) | 2020-08-27 |
| EP3116534A1 (en) | 2017-01-18 |
| EP3116534B1 (en) | 2019-05-29 |
| AU2015229222C1 (en) | 2020-12-24 |
| US11160850B2 (en) | 2021-11-02 |
| NZ724105A (en) | 2023-02-24 |
| US20190231855A1 (en) | 2019-08-01 |
| CN106413744B (zh) | 2020-09-04 |
| TW201620545A (zh) | 2016-06-16 |
| JP6535036B2 (ja) | 2019-06-26 |
| US20150258182A1 (en) | 2015-09-17 |
| CN106413744A (zh) | 2017-02-15 |
| AU2015229222A1 (en) | 2016-09-29 |
| WO2015138847A1 (en) | 2015-09-17 |
| JP2017508806A (ja) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2271515T3 (es) | Composiciones farmaceuticas que comprenden lecitina de union a manosa. | |
| ES2761730T3 (es) | Composiciones y procedimientos para contrarrestar la inhibición del factor Xa | |
| US20130005657A1 (en) | SYNERGISTIC THERAPEUTIC USE OF PROTHROMBIN COMPLEX CONCENTRATES WITH FVlll CONCENTRATES | |
| ES2747815T3 (es) | Preparación que comprende péptidos de factor VIII y factor von Willebrand | |
| US11160850B2 (en) | Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders | |
| ES2689776T3 (es) | Compuestos para el uso para potenciar la coagulación | |
| CA2802072A1 (en) | Treatment of coagulopathy with hyperfibrinolysis | |
| ES2625153T3 (es) | Factor II solo o en combinación con factores adicionales para el tratamiento de la hemostasia alterada asociada con una coagulopatía por dilución | |
| ES2813440T3 (es) | Proteínas prohemostáticas para el tratamiento del sangrado | |
| JP2007513881A (ja) | Ｘｉ因子の治療学的使用 | |
| ES2468225T3 (es) | Estimuladores del factor X activado como nuevos agentes antihemorr�gicos de uso t�pico | |
| ES2913934T3 (es) | Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias | |
| JP2018509398A (ja) | Ｃ１エステラーゼ阻害剤の医薬製剤 | |
| ES2532978T3 (es) | Especialidades farmacéuticas para el tratamiento de trastornos de coagulación de la sangre que contienen concentrado de factor XIa sin trombina | |
| BR112015014926B1 (pt) | combinação compreendendo fator tecidual lipidado, trombina e fibrinogênio, composição selante, composição farmacêutica, uso da referida combinação e kit | |
| ES2288524T3 (es) | Factor xiii en combinacion con factor ix para tratar la hemofilia b. | |
| ES2963665T3 (es) | Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello | |
| US20170042981A1 (en) | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor | |
| JP2006528965A (ja) | 血友病の治療のための第ＶＩＩＩ因子および第ＩＸａ因子を含む組成物 | |
| CN107998375A (zh) | 一种多肽在预防或治疗血栓性疾病或脑缺血再灌注损伤相关疾病中的应用 | |
| JP2016513131A (ja) | 羊水塞栓の治療剤 | |
| TW202400221A (zh) | 凝血因子x活化劑及其用於治療出血性疾病的製劑 | |
| WO2017064213A1 (en) | Method and compounds for treatment and prophylaxis of bleeding episodes | |
| BR112016013591B1 (pt) | Serpina modificada, célula recombinante que expressa a serpina, composição farmacêutica compreendendo a serpina e uso da serpina modificada para o tratamento ou prevenção de hemorragia ou para promoção de hemostasia | |
| EP2579890A1 (en) | Treatment of coagulopathy with hyperfibrinolysis |